|
 |
Lansoprazole Delayed-ReleaseThis page contains recent news articles, when available, and an overview of Lansoprazole Delayed-Release but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Novartis announced the availability of Prevacid 24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail ... pharmabiz.com Teva gets US FDA nod to market generic Prevacid delayed-release capsules - Nov 12, 2009 ...(ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) delayed-release capsules, 15 mg and 30 mg. ... pharmabiz.com Matrix's Lansoprazole approved - Nov 13, 2009 Mylan's Indian subsidiary Matrix Laboratories has received US Food and Drug Administration (FDA) approval for its Lansoprazole delayed-release capsules. ... Pharmacy Europe Teva Receives Final Approval For Generic - Nov 11, 2009 ...(ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid® (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. ... PharmiWeb.com (press release) Novartis unveils Prevacid24HR Over-the-Counter in US for frequent heartburn ... - Nov 12, 2009 ...(lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. ... Trading Markets (press release) Video: Novartis Launches Prevacid(R)24HR Over-the-Counter for Full 24-Hour ... - Nov 12, 2009 Basel, November 12, 2009 /PRNewswire/ — Novartis announced the availability of Prevacid ® 24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) ... PR Newswire (press release) Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its ... - Nov 10, 2009 US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. ... CNNMoney.com (press release) BiomedReports: News and FDA Updates for Teva (Nasdaq:TEVA), Vertex (Nasdaq:VRTX) - Nov 11, 2009 ...(ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. ... Trading Markets (press release) Teva Gets Tentative Approval for Lansoprazole Delayed Release Tablets - Jan 25, 2008 Teva Pharmaceutical Industries has said that the FDA has granted tentative approval for the company's abbreviated new drug application to market ... RedOrbit Article: Heartburn ads treat the pain of drug firms. - Chicago... - Mar 9, 2005 Heartburn ads treat the pain of drug firms. ... find Chicago Tribune (Chicago, IL) articles. Byline: Bruce Japsen CHICAGO _ When government regulators close ... Pay-Per-View - Chicago Tribune - HighBeam Research Company Profile Report - Dec 20, 2008 Market Cap. 7331.754. Current Shares Outstnd. 109.4. Contact Name, Carol A. Cox. Contact Phone, (201)9303300. City, State, Woodcliff Lake, NJ ... $50.00 - Revere Reports - Revere Federal Register 2007 - 72 FR 44159 Determination That PREVACID … - Aug 7, 2007 72 FR 44159 Determination That PREVACID NAPRAPAC (Copackaged Lansoprazole Delayed-Release 15-Milligram Capsules and Naproxen 250-Milligram Tablets) Was Not ... Pay-Per-View - Federal Register 2007 - Loislaw Santarus Announces Positive Results with ZEGERID in Nocturnal Acid … - Mar 8, 2006 SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, ... Free with registration - Business Wire - AccessMyLibrary.com Santarus Announces DDW Clinical Abstract Regarding Nighttime Acid … - May 22, 2006 SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, ... Free with registration - Business Wire - AccessMyLibrary.com Santarus Announces Positive Clinical Results with ZEGERID Capsules in... - Jan 7, 2008 SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced positive results from a recently completed clinical trial ... Free with registration - Business Wire - AccessMyLibrary.com Positive Clinical Data With Santarus' ZEGERID Capsules in Controlling... - May 19, 2008 Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced the presentation of an abstract at the Digestive Disease Week (DDW) annual ... RedOrbit Hot Stock on the Move! January 22, 2007. - Jan 22, 2007 M2 PRESSWIRE-22 January 2007-Wall Street Capital Funding LLC: Hot Stock on the Move! January 22, 2007(C)1994-2007 M2 COMMUNICATIONS LTD. Weston, FLA. ... $4.95 - M2 Presswire - ECNext Video: Novartis Receives Approval From FDA to Market Prevacid(R) … - Dec 31, 2008 BASEL, Switzerland, May 14 /PRNewswire/ -- Novartis announced today that Prevacid(R) 24HR (lansoprazole delayed-release capsules 15 mg) has been approved by ... SmartBrief Santarus Zegerid: better NAB control than Nexium/Prevacid - May 23, 2006 San Diego, USA-based Santarus, a drugmaker focused on gastrointestinal disorders, presented strong clinical data on its proton pump inhibitor, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Santarus Reports Fourth Quarter and Full Year 2007 Financial Results - Mar 3, 2008 Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today reported financial and operating results for the quarter and year ended December 31, ... Genetic Engineering News - Genetic Engineering News (press release) Santarus Zegerid: better NAB control than Nexium/Prevacid. - May 29, 2006 Santarus Zegerid: better NAB control than Nexium/Prevacid. San Diego, USA-based Santarus, a drugmaker focused on gastrointestinal disorders, ... $9.94 - Pharma Marketletter - Alacra Store Santarus Reports First Quarter 2008 Financial Results - May 7, 2008 Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2008. ... Genetic Engineering News - Genetic Engineering News (press release) Teva Provides Update on Generic Prevacid(R) Litigation - Mar 31, 2008 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the US District Court for the District of Delaware has issued a decision in its ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: Perrigo Confirms Patent Challenge of Monistat(R) 1 … - Apr 21, 2008 Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Lialda promotion.(RXs) | Article from Chain Drug Review | HighBeam … - Apr 28, 2008 Lialda promotion.(RXs) ... find Chain Drug Review articles. Shire PLC and TAP Pharmaceutical Products Inc. are copromoting Lialda, indicated for patients ... Pay-Per-View - Chain Drug Review - HighBeam Research Teva Pharmæ›´æ–°å¦å??è?¯Prevacid litigation进度 - Nov 10, 2008 ...(TEVA) 42.21 : å…¬å?¸å®£å¸ƒï¼Œç¾Žå›½è?”邦上诉法院确认2008å¹´3月31日地方法院的判决，å?‘现TAP Pharmaceutical Products的美国第4628,09å?·ä¸“利æ?ƒå…·æœ‰æ•ˆåŠ›å’Œå¼ºåˆ¶æ‰§è¡ŒåŠ›ï¼Œ ... 凤凰网 |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |